Intranasal administration of plasmid DNA-coated nanoparticles results in enhanced immune responses.
Intranasal immunization offers potential forthe elicitation of effective mucosal and systemic immune responses. In this study, a previously reported novel cationic nanoparticle engineered from a microemulsion precursor was further modified, optimized and applied intranasally to mice to explore its potential as a plasmid DNA (pDNA) vaccine delivery system. To this end, more uniform nanoparticles (around 100 nm) containing less cationic surfactant were developed. The pDNA-coated nanoparticles significantly enhanced the specific serum IgG and IgA titres to an expressed model antigen, beta-galactosidase, by 18-28 and 25-30 fold, respectively, when compared with naked pDNA alone. An enhanced splenocyte proliferative response was also observed after immunization with the pDNA-coated nanoparticles. It was concluded that these plasmid DNA-coated nanoparticles may have potential for immunization via the nasal route.
D000281:Administration, Intranasal; D000818:Animals; D016503:Drug Delivery Systems; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D010316:Particle Size; D010957:Plasmids / Q000008:administration & dosage* / Q000276:immunology; D011092:Polyethylene Glycols; D014612:Vaccines / Q000008:administration & dosage / Q000276:immunology*
D014612:Vaccines; D011092:Polyethylene Glycols; C043444:octadecyl polyoxyethylene ether